In September 2022, Nature Biotechnology — one of the most prestigious peer-reviewed journals in the life sciences — published a study that fundamentally repositioned how the scientific community thinks about spirulina. Not as a food supplement or a colour ingredient, but as a biomanufacturing platform for protein-based therapeutics.
The study, "Development of spirulina for the manufacture and oral delivery of protein therapeutics" (DOI: published in Nature Biotechnology 2022; PMC9200632), represented years of work developing genetic engineering tools for Arthrospira platensis — tools that had previously been elusive due to spirulina's resistance to standard genetic manipulation techniques.
For pharmaceutical companies, ingredient companies, and strategic investors in the spirulina space, this publication is a watershed moment — establishing spirulina as a credible platform organism for the next generation of biologic therapeutics.
The Core Discovery: Spirulina as a Protein Biofactory
The research team developed methods for stable, high-level expression of bioactive proteins in spirulina through targeted chromosomal integration. The extraordinary headline finding: engineered proteins can represent as much as 15% of spirulina's total dry weight biomass.
This 15% figure is commercially transformative. Standard fermentation-based protein production (E. coli, CHO cells) requires expensive downstream purification to remove the expression host's endogenous proteins. Spirulina-expressed therapeutic proteins, by contrast:
- Require no purification before oral delivery — the spirulina biomass itself acts as a natural encapsulation matrix
- Are stable without refrigeration — overcoming the cold chain challenge that makes protein biologics expensive to distribute globally
- Are protected during gastric transit when encapsulated within dry spirulina — addressing the critical oral bioavailability challenge for protein therapeutics
The Phase 1 Clinical Trial: Human Safety Demonstrated
The research team didn't stop at the laboratory bench. They developed an antibody targeting Campylobacter jejuni — a major cause of infant mortality through diarrhoeal disease in the developing world — expressed in spirulina biomass, and advanced it through a Phase 1 clinical trial demonstrating safety for human administration.
This represents the first documented human clinical trial of a spirulina-expressed protein therapeutic, and its safety data in human subjects marks a milestone in the regulatory pathway for this entire drug delivery modality.
The Implications: Beyond Supplements, Into Pharma
The Nature Biotechnology paper has several profound implications for the spirulina industry:
1. Therapeutic value of high-biomass production: Spirulina farms producing genetically engineered therapeutic-expressing biomass would command pharmaceutical-grade pricing — potentially orders of magnitude above conventional food supplement pricing. The demand for reliable, high-quality, pharma-grade spirulina biomass as a starting material for this platform is a long-term structural demand driver.
2. India's advantage in this scenario: India's spirulina cultivation infrastructure, combined with its existing pharmaceutical manufacturing ecosystem and proximity to research institutions (CSIR-IICT, IIT Hyderabad, CCMB), positions it uniquely to serve as a production hub for this emerging sector.
3. Oral delivery is the key value proposition: The global oral biologics market is projected to exceed $15 billion by 2030. The cold-chain-free, no-purification-required oral delivery platform that spirulina offers addresses the highest-cost constraints in current biologic drug production.
The Broader Biotechnology Context
The spirulina drug delivery paper is not an isolated data point. It connects with the broader trend of using food-safe organisms as pharmaceutical platforms — a field sometimes called "edible vaccines" or "plant-made pharmaceuticals." Spirulina's advantages over plant-based systems include faster growth rates, higher biomass yield per unit area, and a well-established safety record in human consumption.
→ For context on phycocyanin's pharmaceutical applications at current commercial grades, see: [Phycocyanin Purity Grades Explained: E18, E25, E30 — Which Grade Does Your Application Need?]
→ For the neuroprotective pharmaceutical applications of current E30 grade: [The Neuroprotection Frontier: Can Phycocyanin Help with Alzheimer's and Parkinson's Disease?]
Scientific References
Doron L et al. (2022). "Development of spirulina for the manufacture and oral delivery of protein therapeutics." Nature Biotechnology, Open Access, September 2022. DOI: [Nature Biotechnology 2022]. PMC9200632. https://www.nature.com/articles/s41587-022-01249-7
Karizi SR et al. (2023). Phytotherapy Research. (Wider spirulina therapeutic context.)
Market context: Pharmaceutical Grade Phycocyanin Market Report. Market Research Intellect, September 2024. https://www.marketresearchintellect.com/blog/beyond-beauty-how-pharmaceutical-grade-phycocyanin-is-transforming-health-products/
◦ Tagged
◦ Premium Download
Get the typeset PDF report.
Branded, beautifully formatted, sharable with your procurement, R&D, and formulation teams.
About the Author
Sripal Reddy Molugu
Co-Founder & CTO, Spiruva
Spiruva's editorial team includes co-founders and industry researchers covering the global phycocyanin and spirulina markets. We publish data-driven articles that help B2B buyers make better procurement decisions.